Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

During the last three months, 4 analysts shared their evaluations of Liquidia LQDA, revealing diverse outlooks from bullish ...

Liquidia Co. (NASDAQ:LQDA – Get Free Report) gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $14.74, but opened at $14.38 ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...

The stability of treprostinil sodium after dilution in three common i.v. infusion vehicles was assessed. The chemical stability of treprostinil sodium was tested over a 48-hour period at 40 °C ...

Commercially available solutions of treprostinil sodium a, b were diluted in sterile water for injection, c 0.9% sodium chloride injection, d and 5% dextrose injection. e The concentrations tested ...

Liquidia intends to use the proceeds to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH ...

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat ...